Roel van Kampen

407 total citations
8 papers, 167 citations indexed

About

Roel van Kampen is a scholar working on Oncology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Roel van Kampen has authored 8 papers receiving a total of 167 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 3 papers in Genetics and 2 papers in Pathology and Forensic Medicine. Recurrent topics in Roel van Kampen's work include Chronic Lymphocytic Leukemia Research (3 papers), CAR-T cell therapy research (2 papers) and Atrial Fibrillation Management and Outcomes (2 papers). Roel van Kampen is often cited by papers focused on Chronic Lymphocytic Leukemia Research (3 papers), CAR-T cell therapy research (2 papers) and Atrial Fibrillation Management and Outcomes (2 papers). Roel van Kampen collaborates with scholars based in Netherlands, United States and United Kingdom. Roel van Kampen's co-authors include Arnon P. Kater, Eric Eldering, Simon P. Mackay, Elaine Willmore, Louise Young, Christopher M. West, Rachel Thijssen, Franchette van den Berkmortel, Vivianne C. G. Tjan‐Heijnen and Maaike de Boer and has published in prestigious journals such as Cell Death and Differentiation, Oncotarget and Toxicology Letters.

In The Last Decade

Roel van Kampen

7 papers receiving 162 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Roel van Kampen Netherlands	5	75	40	37	34	30	8	167
Kian Meng Chang Malaysia	8	28 0.4×	71 1.8×	10 0.3×	33 1.0×	17 0.6×	29	198
Rupali Bhave United States	6	46 0.6×	18 0.5×	16 0.4×	67 2.0×	7 0.2×	18	168
Jayeshkumar Patel United States	10	47 0.6×	16 0.4×	8 0.2×	79 2.3×	27 0.9×	21	221
Jamal Misleh United States	7	93 1.2×	37 0.9×	23 0.6×	48 1.4×	10 0.3×	24	204
Gustav Magrinat United States	7	120 1.6×	13 0.3×	43 1.2×	15 0.4×	9 0.3×	10	184
Rakchha Chhetri Australia	9	20 0.3×	88 2.2×	22 0.6×	26 0.8×	11 0.4×	25	219
Mahmoud Elsawy United States	7	62 0.8×	62 1.6×	18 0.5×	51 1.5×	9 0.3×	15	244
Sandra Maria Dold Germany	6	125 1.7×	15 0.4×	29 0.8×	149 4.4×	8 0.3×	9	255
Susann Theile Denmark	9	207 2.8×	11 0.3×	13 0.4×	71 2.1×	48 1.6×	26	303
Thuy T. Koll United States	11	99 1.3×	20 0.5×	104 2.8×	79 2.3×	5 0.2×	24	297

Countries citing papers authored by Roel van Kampen

Since Specialization

Citations

This map shows the geographic impact of Roel van Kampen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roel van Kampen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roel van Kampen more than expected).

Fields of papers citing papers by Roel van Kampen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roel van Kampen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roel van Kampen. The network helps show where Roel van Kampen may publish in the future.

Co-authorship network of co-authors of Roel van Kampen

This figure shows the co-authorship network connecting the top 25 collaborators of Roel van Kampen. A scholar is included among the top collaborators of Roel van Kampen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roel van Kampen. Roel van Kampen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Cretenet, Gaspard, Roel van Kampen, Aldo Jongejan, et al.. (2024). T-cell dysfunction in CLL is mediated through expression of Siglec-10 ligands CD24 and CD52 on CLL cells. Blood Advances. 8(17). 4633–4646. 9 indexed citations

Rodrigues, Daniela, Roel van Kampen, Ad A. van Bodegraven, et al.. (2022). Gene expression responses reflecting 5-FU-induced toxicity: Comparison between patient colon tissue and 3D human colon organoids. Toxicology Letters. 371. 17–24. 4 indexed citations

Thijssen, Rachel, Christopher M. West, Louise Young, et al.. (2021). Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL. Cell Death and Differentiation. 28(5). 1658–1668. 66 indexed citations

Janknegt, Robert, et al.. (2020). Direct Oral Anticoagulants: Drug Selection by Means of the SOJA Method. Acta Scientific Pharmaceutical Sciences. 4(12). 95–119. 3 indexed citations

Janknegt, Robert, et al.. (2020). Direct Oral Anticoagulants: Drug Selection by Means of the SOJA Method. Acta Scientific Pharmaceutical Sciences. 4(12). 120–144. 1 indexed citations

Martens, Anne W. J., Ingrid A. M. Derks, Homer Adams, et al.. (2020). CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells. Journal for ImmunoTherapy of Cancer. 8(1). e000218–e000218. 19 indexed citations

Berkmortel, Franchette van den, Marjan van den Akker, Laura Deckx, et al.. (2017). Functional status decline in older patients with breast and colorectal cancer after cancer treatment: A prospective cohort study. Journal of Geriatric Oncology. 8(3). 176–184. 56 indexed citations

Lobbezoo, D.J.A., Wilfred Truin, Adri C. Voogd, et al.. (2016). The role of histological subtype in hormone receptor positive metastatic breast cancer: similar survival but different therapeutic approaches. Oncotarget. 7(20). 29412–29419. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact